Leerink Partners maintains AbbVie at Outperform, raises price target to $342 from $309

What happened

Leerink Partners kept its Outperform rating on AbbVie and raised its price target to $342 from $309, a 10.7% increase. The new target implies 16.0% upside from AbbVie’s October 30 closing price of $294.89.

Confirmed

Global impact / market context

A higher target signals that Leerink sees more potential value in AbbVie shares, but it does not change the company’s sales, costs, or cash available. If investors give the view weight, their buying or selling could influence the share price; the target is not a guarantee.

Analyst inference

The five most recent analyst notes cited in the article set targets between $322 and $346, placing Leerink’s $342 target near the high end. These are analysts’ estimates, not company results, and the article gives no evidence of a resulting share-price move.

Confirmed

What to watch

1. Compare upcoming analyst targets with Leerink’s $342 and the cited $322–$346 range to see whether views on AbbVie’s potential share value are changing. Analyst inference
2. Check whether AbbVie reports business results or guidance that supports or challenges the expectations behind analysts’ targets; the article provides no operating forecast. Analyst inference
3. Watch how AbbVie shares trade relative to the October 30 close of $294.89; the article’s 16.0% implied upside is based on that reference price. Analyst inference

Evidence

• Original source link unavailable